NEW HAVEN, Conn., Feb. 5 /PRNewswire/ -- Achillion Pharmaceuticals, Inc. today announced that John C. Pottage, M.D., Achillion's Chief Medical Officer, will participate in a panel discussion on Monday, February 12 at the 2007 BIO CEO and Investor Conference in New York City. The panel is a Therapeutic Workshop scheduled for 3:30 p.m. (EST) entitled, "Novel HIV Therapies." Details about the conference, including webcast information, can be found on the conference website at http://www.ceo.bio.org.
About Achillion
Achillion is a biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for infectious diseases. Achillion is currently developing treatments for HIV infection, chronic hepatitis C infection and serious hospital-based bacterial infections. For more information on Achillion Pharmaceuticals, please visit the company's web site at www.achillion.com or call Achillion at 1-203-624-7000.
Contact: Mary Kay Fenton Achillion Pharmaceuticals, Inc. Tel. (203) 624-7000 mfenton@achillion.com Media: Kari Watson MacDougall Biomedical Communications, Inc. Tel. (508) 647-0209 kwatson@macbiocom.com
Achillion Pharmaceuticals, Inc.CONTACT: Mary Kay Fenton of Achillion Pharmaceuticals, Inc.,+1-203-624-7000, or mfenton@achillion.com, or Media, Kari Watson, ofMacDougall Biomedical Communications, Inc., +1-508-647-0209, orkwatson@macbiocom.com, for Achillion Pharmaceuticals, Inc.
